{
    "Trade/Device Name(s)": [
        "Carbamazepine",
        "Valproic Acid",
        "TDM Calibration set B"
    ],
    "Submitter Information": "Thermo Fisher Scientific Oy",
    "510(k) Number": "K063131",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "KLT",
        "LEG",
        "DKB"
    ],
    "Summary Letter Date": "October 5, 2007",
    "Summary Letter Received Date": "September 27, 2007",
    "Submission Date": "September 25, 2007",
    "Regulation Number(s)": [
        "21CFR862.3645"
    ],
    "Regulation Name(s)": [
        "Neuroleptic drugs radioreceptor assay test system"
    ],
    "Analyte Class(es)": [
        "tdm",
        "toxicology",
        "chemistry"
    ],
    "Analyte(s)": [
        "Carbamazepine",
        "Valproic acid"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "T60 Clinical Chemistry Analyzer",
        "DPC T60i",
        "DPC T60i Kusti"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay"
    ],
    "Methodologies": [
        "Enzyme immunoassay",
        "Recombinant DNA technology"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Thermo Fisher Scientific Oy's Carbamazepine and Valproic Acid assays and TDM Calibration set B for quantification in human serum using T60 analyzers.",
    "Indications for Use Summary": "For in vitro quantitative determination of carbamazepine and valproic acid concentrations in human serum using T60 Clinical Chemistry Analyzers; used in diagnosis, treatment, and therapeutic monitoring of overdose for both drugs; calibrator for measurement of these assays on T60 Analyzer.",
    "fda_folder": "Toxicology"
}